Clinical Trial Update: MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial MOONRAY-01 evaluating LY3962673 in KRAS G12D-mutant solid tumors is currently recruiting. The study appears to include pancreatic ductal adenocarc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• LY3962673 (LY3962673)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer | Phase 1 | Status: RECRUITING